Taken together, our study suggests that Src and c-Abl are potential therapeutic targets in NB and that novel Src/Abl inhibitors like bosutinib alone or in combination with other chemotherapeutic agents may benefit NB patients. This evidence concerns the gene ABL1 and neuroblastoma.